Evidence map›Paper›PMID 29844871›Full record

ArticleOncotarget2018

Pericytes/vessel-associated mural cells (VAMCs) are the major source of key epithelial-mesenchymal transition (EMT) factors SLUG and TWIST in human glioma.

Lisa Mäder, Anna E Blank, David Capper, Janina Jansong, Peter Baumgarten, Naita M Wirsik, Cornelia Zachskorn, Jakob Ehlers, Michael Seifert, Barbara Klink and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 8 institutions in 2 countries.

Lisa MäderEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Anna E BlankEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
David CapperDepartment of Neuropathology, University of Heidelberg, Heidelberg, Germany.
Janina JansongLaboratory of Molecular Neuro-Oncology, Department of Vascular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Peter BaumgartenEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Naita M WirsikEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Cornelia ZachskornEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Jakob EhlersCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Neuropathology, Berlin, Germany.
Michael SeifertCarl Gustav Carus Faculty of Medicine, Technische Universität Dresden, Institute for Medical Informatics and Biometry (IMB), Dresden, Germany.
Barbara KlinkInstitute for Clinical Genetics, Faculty of Medicine Carl Gustav Carus, Dresden University of Technology, Dresden, Germany.
Stefan LiebnerEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Simone NiclouNORLUX Neuro-Oncology Laboratory, Luxembourg Institute of Health (LIH), Strassen, Luxembourg.
Ulrike NaumannLaboratory of Molecular Neuro-Oncology, Department of Vascular Neurology, Hertie Institute for Clinical Brain Research, University of Tübingen, Tübingen, Germany.
Patrick N HarterEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Michel MittelbronnEdinger Institute (Neurological Institute), Goethe University, Frankfurt, Germany.
Goethe University Frankfurt · DEDeutschen Konsortium für Translationale Krebsforschung · DEUniversity Hospital Carl Gustav Carus · DEUniversity of Tübingen · DECharité - Universitätsmedizin Berlin · DEFreie Universität Berlin · DEGerman Cancer Research Center · DELuxembourg Institute of Health · LU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epithelial-to-mesenchymal transition (EMT) is supposed to be responsible for increased invasion and metastases in epithelial cancer cells. The activation of EMT genes has further been proposed to be important in the process of malignant transformation of primary CNS tumors. Since the cellular source and clinical impact of EMT factors in primary CNS tumors still remain unclear, we aimed at deciphering their distribution

Indexed as

EMTgliomasMETpericytesvessel-associated mural cells

Identifiers

PMID29844871
PMCPMC5963615
OpenAlexW2802830840

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.